NCT05468632 - A Study in North Macedonia Investigating Retrospective Data of Glucagon-like Peptide-1 (GLP-1) Participants With Type 2 Diabetes (T2D) in Real World Environment (RWE) Setting (MIRAGE) | Biotech Hunter

Enrollment

314

Participants

Timeline

Start Date

July 5, 2022

Primary Completion Date

July 31, 2022

Study Completion Date

July 31, 2022

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Semaglutide

Participants who initiated once weekly (OW) semaglutide in routine clinical practice in were enrolled in the study. The participants were treated according to current clinical practice, applicable local labels, and standard of care as per physicians' discretion.

Trial Locations (17)

1000

Novo Nordisk Investigational Site, Skopje

1220

Novo Nordisk Investigational Site, Tetovo

1230

Novo Nordisk Investigational Site, Gostivar

1250

Novo Nordisk Investigational Site, Debar

1300

Novo Nordisk Investigational Site, Kumanovo

1400

Novo Nordisk Investigational Site, Veles

1430

Novo Nordisk Investigational Site, General Hospital Kavadarci

2000

Novo Nordisk Investigational Site, Shtip

2300

Novo Nordisk Investigational Site, Kočani

2400

Novo Nordisk Investigational Site, Stumica

6000

Novo Nordisk Investigational Site, Ohrid

6250

Novo Nordisk Investigational Site, Kičevo

6330

Novo Nordisk Investigational Site, Struga

7000

Novo Nordisk Investigational Site, Bitola

7500

Novo Nordisk Investigational Site, Prilep

1 000

Novo Nordisk Investigational Site, Skopje

SK 1000

Novo Nordisk Investigational Site, Skopje